The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Tumor-wide RNA splicing aberrations and their potential as therapeutic neoantigen targets.
 
Darwin Kwok
No Relationships to Disclose
 
Nicholas Stevers
No Relationships to Disclose
 
Inaki Etxeberria
No Relationships to Disclose
 
Takahide Nejo
No Relationships to Disclose
 
Maggie Colton Cove
No Relationships to Disclose
 
Lee Chen
No Relationships to Disclose
 
Jangham Jung
No Relationships to Disclose
 
Kaori Okada
No Relationships to Disclose
 
Senthilnath Lakshmanachetty
No Relationships to Disclose
 
Marco Gallus
No Relationships to Disclose
 
Abhilash Barpanda
No Relationships to Disclose
 
Chibo Hong
No Relationships to Disclose
 
Aaron Diaz
No Relationships to Disclose
 
Shawn Hervey-Jumper
Research Funding - NIH
 
Susan Chang
No Relationships to Disclose
 
Joanna Phillips
No Relationships to Disclose
 
Arun Wiita
Research Funding - Quadriga Biosciences; Sutro Biopharma; TeneoBio
 
Christopher Klebanoff
Stock and Other Ownership Interests - Achilles Therapeutics; Affini-T Therapeutics; CVS Health; DaVita; Gilead Sciences; Obsidian Therapeutics
Honoraria - Kite, a Gilead company
Consulting or Advisory Role - Achilles Therapeutics; Affini-T Therapeutics; Aleta Biotherapeutics; Bellicum Pharmaceuticals; Bristol-Myers Squibb; Catamaran Bio; Cell Design Labs; G1 Therapeutics; Klus Pharma; Obsidian Therapeutics; Roche/Genentech; Royalty Pharma; RXI Pharmaceuticals; T-Knife
Research Funding - Affini-T Therapeutics; Intima; Kite, a Gilead company (Inst); Lilly (Inst); Roche/Genentech (Inst)
Patents, Royalties, Other Intellectual Property - Patents related FAS dominant receptors and uses in CAR-modified NK cells.; Patents related to TCRs targeting a shared PIK3CA neoantigen.; Patents related to TCRs targeting shared hotspot mutations in KRAS G12D, NRAS Q61R/K/L, and P53 (R175H)
 
Joseph Costello
No Relationships to Disclose
 
Hideho Okada
Consulting or Advisory Role - Chimeric Therapeutics; NEUVOGEN
Patents, Royalties, Other Intellectual Property - EGFRvIII-CAR - an exclusive licensing agreement has been executed with Novartis Pharma; IL-13Ra2 (345-353:1A9V) exclusive licensing agreement has been executed with Stemline, Inc.; Inventor of US utility patent application (Case #: SF2015-163) has been filed for H3.3 CTL peptides and uses thereof.; Inventor of US utility patent application (Case #: SF2015-163) has been filed for H3.3 CTL peptides and uses thereof.; Three US provisional patients have been published (PCT/US2019/025846, PCT/US2019/025829, PCT/US2019/025860) for the use of synNotch circuits for treatment of solid cancers, including glioblastoma